Viatris agreed to buy Pacira BioSciences for $1.65 billion in cash at $36.50 per share, a ~45% premium to Wednesday's $25.20 close, adding non-opioid pain drugs Exparel and Zilretta. Pacira surged 44% Thursday toward its largest single-day gain on record; the deal is slated to close by year end and will be funded mainly from excess cash.
Useful?